MindRank AI Presents Breakthroughs in AI-Driven Drug Discovery at Qiantang 'AI + Biopharma' Innovation Symposium
MindRank
AI Drug Developer
August 27, 2025Hangzhou Qiantang District Hosts "AI + Biomedicine" Innovation SeminarMedia Press Tour. Government leaders of Qiantang New District, academic experts, and corporate leaders jointly discussed how artificial intelligence technology can empower life sciences and solve R&D challenges.MindRank Founder and CEO Zhangming Niu Invited to Attend and Deliver a Keynote SpeechAfter the meeting, government leaders and media from all walks of life came to visit and investigate MindRank.
MindRank, a key biopharmaceutical enterprise introduced to the Qiantang District, is always committed to reconstructing drug R&D pathways using cutting-edge technologies such as artificial intelligence. The company’s self-developed “industrial-grade one-stop AI-driven new drug R&D platform” utilizes clustered and engineered AI technology, which is expected to reduce early-stage costs and R&D cycles of new drug development by 50% or more. In May this year, MindRank's first AI-assisted designed GLP-1RA oral small molecule drug, MDR-001, completed Phase IIb clinical trials. Clinical results showed that patients achieved an average weight loss of over 10.3% at 24 weeks (before placebo calibration), with excellent safety and tolerability. The project confirmed PCC just eight months after initiation.
MindRank's rapid development benefits from the high-quality industrial policies and innovative ecological environment in Qiantang District. Qiantang District continues to deepen the "six-chain integration" development model, which includes innovation chain, industry chain, talent chain, policy chain, financial chain, and service chain, while taking an early lead in laying out the new track of "AI + biomedicine," providing enterprises with a resource-sharing and complementary-advantage entrepreneurial and innovative environment. In the future, MindRank will continue to focus on the innovation and iteration of AI pharmaceutical systems and further advance the research and development of innovative drugs in metabolic and oncological diseases, striving for the well-being of patients and promoting high-quality growth in China’s AI biomedicine industry.QuantityContribute to development.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and highly clinically valuable drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby enabling more diseases to be treatable and allowing more lives to regain health.
The company owns a self-developed, internationally leading industrial-grade one-stop AI-driven innovative drug R&D platform, including the knowledge graph-based data mining platform PharmKG™, the protein dynamic simulation and structure prediction platform Molecule Dance™, and the one-stop AI drug design platform Molecule Pro™.
MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020" by the authoritative European and American institution, Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT list as one of "China's most socially influential startups."
MindRank's Self-Developed One-Stop AI Pharmaceutical Platform
Related Reading:
MindRank's Self-Developed WEE1/YES1 Dual Inhibitor Receives FDA Clinical Approval
MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region
For more information, please visit the website: www.mindrank.ai
Contact: bd@mindrank.ai pr@mindrank.ai
Other: info@mindrank.ai